Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Firefly Aerospace Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a report indicating that Firefly Aerospace may have misled investors regarding its business performance [1]. - Investors who purchased Firefly Aerospace securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. Group 2: Financial Performance - Firefly Aerospace reported a wider loss and lower revenue in its latest quarter, which was its first earnings report since going public [3]. - Following the earnings report, Firefly's stock price fell by 15.3% on September 23, 2025 [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by December 8, 2025 [3][6]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [6]. - A report from NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions, including a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [7]. - Following the release of the report, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 on heavy trading volume [9]. Group 2: Legal Actions and Investor Options - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995, indicating its capability in handling such cases [5]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [10].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by December 2, 2025 [2][5]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Molina to contact them regarding their legal rights [1][2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements and failed to disclose material adverse facts regarding the company's medical cost trend assumptions [5]. - Specific issues cited include a dislocation between premium rates and medical costs, dependence on low utilization of various health services, and the likelihood of cutting financial guidance for fiscal year 2025 [5]. Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures [6]. - The company cut its full-year adjusted earnings per share guidance by 10.2%, from at least $24.50 to a range of $21.50 to $22.50 [7]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share [7]. - On July 23, 2025, Molina further slashed its full-year earnings guidance, reporting a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year over year [8]. - The new guidance indicated a 13.6% cut to earnings per share, with full-year GAAP net income guidance reduced by 27% to $912 million [8]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of false and misleading statements regarding its product SLK, which failed to demonstrate competitive efficacy compared to BIMZELX, leading to significant stock price decline [2][5][6][8]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in MoonLake to contact them for discussing legal options [1]. - There is a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against MoonLake [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the differences between Nanobodies and monoclonal antibodies [5]. - Specific allegations include misleading claims about SLK's clinical benefits and its supposed superiority over BIMZELX, which were not supported by evidence [5]. - Following the announcement of disappointing Phase 3 trial results, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 [6][8].

Core Viewpoint - WPP plc is facing a class action lawsuit due to allegations of misleading statements regarding its expected revenue for fiscal year 2025, which led to significant financial losses for investors [5][6]. Group 1: Legal Action and Investor Information - Faruqi & Faruqi, LLP is investigating potential claims against WPP and reminds investors of the December 8, 2025 deadline to seek the role of lead plaintiff in the class action lawsuit [2]. - Investors who purchased WPP securities between February 27, 2025, and July 8, 2025, are encouraged to contact the law firm to discuss their legal rights [1][2]. Group 2: Allegations Against WPP - The complaint alleges that WPP and its executives violated federal securities laws by making false and misleading statements about the company's media division and its ability to handle macroeconomic challenges [5]. - WPP's executives claimed that new business wins would offset losses, while concealing the true state of the media arm, which was losing market share [5]. Group 3: Market Reaction - Following WPP's trading update on July 9, 2025, which indicated a deterioration in performance, the company's stock price fell from $35.82 to $29.34, a decline of approximately 18.1% in one day [6][7].

Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [5][6]. Group 1: Legal Action and Investor Information - Faruqi & Faruqi, LLP is investigating potential claims against Baxter and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in the class action lawsuit [2]. - Investors who suffered losses from Baxter's securities between February 23, 2022, and July 30, 2025, are encouraged to contact the law firm to discuss their legal rights [1][2]. Group 2: Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions and posed risks of serious injury or death to patients [5]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to the Novum LVP but did not take adequate remedial measures [5]. - Following the announcement on July 31, 2025, regarding the voluntary pause of shipments and installations of the Novum LVP, Baxter's stock price dropped by 22.4%, closing at $21.76 [6][7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against James Hardie Industries plc for misleading investors regarding the performance of its North America Fiber Cement segment, with a class action lawsuit deadline set for December 23, 2025 [2][5]. Group 1: Legal Action and Investor Information - Investors who suffered losses exceeding $100,000 in James Hardie between May 20, 2025, and August 18, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - A federal securities class action has been filed against James Hardie, with a deadline for seeking the role of lead plaintiff on December 23, 2025 [2]. - The lead plaintiff in a class action is typically the investor with the largest financial interest who directs the litigation on behalf of the class [7]. Group 2: Allegations Against James Hardie - The complaint alleges that James Hardie and its executives violated federal securities laws by making false statements and failing to disclose the true state of its North America Fiber Cement segment [5]. - Despite knowing about inventory destocking by distributors, James Hardie falsely claimed that demand remained strong and stock levels were normal [5]. - Following the announcement of a 29% decline in first-quarter profit and lower-than-expected fiscal 2026 earnings, James Hardie's ADR price fell by $9.79, or 34.44%, closing at $18.64 on August 20, 2025 [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Avantor, Inc. for alleged violations of federal securities laws, encouraging affected investors to participate in a class action lawsuit [2][5]. Group 1: Allegations Against Avantor - The complaint alleges that Avantor and its executives made false and misleading statements regarding the company's competitive positioning and the impact of increased competition [5]. - Specific claims include that Avantor's competitive position was weaker than represented, and that the company was negatively affected by heightened competition [5][6]. - During an earnings call on July 26, 2024, the then-CEO assured investors of Avantor's strong competitive position, which later proved to be misleading [6]. Group 2: Financial Performance and Stock Impact - On April 25, 2025, Avantor reported disappointing Q1 2025 results, cutting its guidance and announcing the CEO's resignation, leading to a stock price drop of over 16.5% [7]. - The company continued to report poor financial results, including a year-over-year decrease in net sales for Q2 2025, further reducing its 2025 guidance to a projected organic revenue growth of -2% to 0% [8]. - By October 29, 2025, Avantor reported a net loss of $712 million for Q3 2025, primarily due to a non-cash goodwill impairment charge of $785 million, attributed to competitive pressures [10]. - Following the Q3 report, Avantor's stock price fell by more than 23% [11].

Core Viewpoint - CarMax is facing a class action lawsuit due to allegations of misleading statements regarding its growth prospects and financial performance, particularly related to its loan loss provisions and stock price decline [5][6][7]. Group 1: Legal Proceedings - Faruqi & Faruqi, LLP is investigating potential claims against CarMax and reminds investors of the January 2, 2026 deadline to seek the role of lead plaintiff in the federal securities class action [2]. - The lawsuit claims that CarMax and its executives violated federal securities laws by making false statements about the company's growth and failing to disclose critical information [5]. - Investors who suffered losses between June 20, 2025, and September 24, 2025, are encouraged to contact the law firm to discuss their legal rights [1]. Group 2: Financial Performance - CarMax reported a significant decrease in income from CarMax Auto Finance, with an 11.2% decline attributed to a $142.2 million provision for loan losses in the second quarter of fiscal 2026, compared to $112.6 million in the same period the previous year [6]. - The provision for loan losses included a $71.3 million increase in estimated lifetime losses on existing loans, primarily due to worsening performance among the 2022 and 2023 vintages [7]. - Following the financial results announcement, CarMax's stock price fell by $11.45 per share, approximately 20%, closing at $45.60 on September 26, 2025 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Primo Brands Corporation due to alleged violations of federal securities laws related to misleading statements about the merger with BlueTriton Brands and its integration process [2][5]. Group 1: Allegations and Impact - The complaint alleges that Primo Brands and its executives made false and misleading statements regarding the merger, leading investors to believe it would enhance growth and operational efficiencies [5]. - Issues began to surface on August 7, 2025, when Primo Brands reported Q2 2025 earnings, revealing disruptions in product supply and service due to the merger [5]. - Following the August 7 disclosure, the stock price fell by $2.41, approximately 9%, from $26.41 to $24.00 [5]. - On November 6, 2025, the company significantly reduced its full-year 2025 net sales and adjusted EBITDA guidance, and announced the replacement of CEO Rietbroek [6]. - New CEO Eric Foss acknowledged that the company had moved "too far too fast" with integration efforts, resulting in various operational issues [6]. Group 2: Stock Performance - After the November 6 disclosure, the stock price dropped by $8.20, or 36%, over the next two trading sessions, falling from $22.66 to $14.46 [7]. Group 3: Legal Proceedings - Investors who suffered losses during the specified class period are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][2]. - The deadline to seek the role of lead plaintiff in the federal securities class action against Primo Brands is January 12, 2026 [2].